252 results on '"Law, Jennie Y."'
Search Results
2. CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant
3. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy
4. Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis
5. Trouble afoot: Mycosis fungoides bullosa at an unusual site
6. Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses
7. Diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH) in sickle cell disease: A review
8. Utility of Hemoglobin Electrophoresis to Distinguish Between Severe Delayed Hemolytic Transfusion Reaction Versus Hyperhemolysis Syndrome
9. Macrophage activation syndrome after granulocyte colony‐stimulating factor in a patient with systemic lupus erythematosus
10. Risks associated with fertility preservation for women with sickle cell anemia
11. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation
12. Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis
13. Fulminant Hepatic Failure as the Initial Presentation of Hodgkin Lymphoma in 4 Patients With Human Immunodeficiency Virus
14. An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study
15. Clinical Outcomes of Axi-Cel CAR-T Cell Therapy in Elderly Versus Younger Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Experience
16. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
17. Recurrent Fevers in a Patient With Splenomegaly.
18. Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
19. Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance
20. Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
21. Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?
22. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
23. Gastrointestinal Vasoocclusive Crisis in a Woman with Hemoglobin SC Disease
24. Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
25. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy
26. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
27. Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
28. A Seemingly Solitary Bone Lesion
29. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma
30. CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma
31. Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy
32. Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy
33. Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease
34. The Impact of IDH1c.315C>T Single Nucleotide Polymorphism on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
35. Lymphadenopathy and Jaundice
36. Pancytopenia in a Cameroonian Patient with AIDS
37. The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma
38. MDS-426: Cardiovascular Disease and Marrow Vascular Markers in Patients with Myeloid Malignancies
39. IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial
40. Poster: MDS-426: Cardiovascular Disease and Marrow Vascular Markers in Patients with Myeloid Malignancies
41. Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial
42. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
43. Isolated thrombocytopenia and liver function abnormalities characterizing an atypical presentation of thrombotic thrombocytopenic purpura
44. 247 - Clinical Outcomes of Axi-Cel CAR-T Cell Therapy in Elderly Versus Younger Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Experience
45. Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
46. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
47. Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
48. Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
49. Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia
50. Macrophage activation syndrome after granulocyte colony‐stimulating factor in a patient with systemic lupus erythematosus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.